FDA removes Boxed Warning about risk of leg and foot amputations for canagliflozin

Based on review of new data from 3 clinical trials, FDA has removed Boxed Warning about amputation risk from canagliflozin prescribing information as the risk, while still increased with canagliflozin, is lower than previously described, particularly when appropriately monitored.


US Food and Drug Administration